In our hypothesis; http://www.sciencedirect.com/science/article/pii/S0306987711004671
DRD3ser/ser is a requirement for the expression of trait A, although it is very likely not a sufficient condition. We posited that schizophrenia could be divided into two general groups, those who have the genotype DRD3ser/ser and those who do not. That is, individuals, of genotype gly/gly or gly/ser would lack trait A, hence they would necessarily be N or NP types. (The ser/ser genotype would correspond to a mixture of individuals: those with A or A− trait, as well as some N or NP types in whom the A trait is blocked because of other mechanisms).
Thus, as in the Iranian autism study cited, the gly/gly and gly/ser children would be N or NP types. The ser/ser group would contain a mixture of types, but all of the A, PA, NA and NPA+ types, as well as all of the children with A− trait.
For Iran, we found it to be a basically sanguine, polymorphic habitancy, with a high prevalence of A trait. Nevertheless, there was recognizable non-sanguinity, perhaps on the average of 5 to 10 percent. The prevalence of A− trait is unknown (although it has been idenfified in nearby Turkey).
So, in the context of our hypothesis, the Iranian study found that Risperidone was more effective in N and NP children who had the diagnosis of autism. Perhaps the non-responders were mainly ser/ser autistic children who had the A− trait.
Note that the Iranian study was a small one, but it could be a starting point for a more intensive study.
« Back to index